Aequus Pharmaceuticals (CVE:AQS) and NeutriSci International (CVE:NU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Analyst Recommendations
This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and NeutriSci International, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Aequus Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
NeutriSci International | 0 | 0 | 0 | 0 | N/A |
Valuation & Earnings
This table compares Aequus Pharmaceuticals and NeutriSci International's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Aequus Pharmaceuticals | C$2.28 million | 11.50 | C$-2,880,394.00 | C($0.02) | -9.09 |
NeutriSci International | C$69,626.00 | 416.05 | C$-1,982,032.00 | C($0.01) | -14.62 |
NeutriSci International has lower revenue, but higher earnings than Aequus Pharmaceuticals. NeutriSci International is trading at a lower price-to-earnings ratio than Aequus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Aequus Pharmaceuticals and NeutriSci International's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Aequus Pharmaceuticals | N/A | N/A | N/A |
NeutriSci International | N/A | N/A | N/A |
Summary
NeutriSci International beats Aequus Pharmaceuticals on 3 of the 5 factors compared between the two stocks.